These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15604987)

  • 21. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new rabbit monoclonal antibody (4B5) for the immuno-histochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
    Powell WC; Roche PC; Tubbs RR
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):569. PubMed ID: 18931613
    [No Abstract]   [Full Text] [Related]  

  • 23. Validation of a fully automated HER2 staining kit in breast cancer.
    Moelans CB; Kibbelaar RE; van den Heuvel MC; Castigliego D; de Weger RA; van Diest PJ
    Cell Oncol; 2010; 32(1-2):149-55. PubMed ID: 20203372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
    Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.
    Eppenberger-Castori S; Kueng W; Benz C; Caduff R; Varga Z; Bannwart F; Fink D; Dieterich H; Hohl M; Müller H; Paris K; Schoumacher F; Eppenberger U
    J Clin Oncol; 2001 Feb; 19(3):645-56. PubMed ID: 11157014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z; Noske A
    PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.
    Mouttet D; Laé M; Caly M; Gentien D; Carpentier S; Peyro-Saint-Paul H; Vincent-Salomon A; Rouzier R; Sigal-Zafrani B; Sastre-Garau X; Reyal F
    PLoS One; 2016; 11(2):e0146474. PubMed ID: 26829108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer.
    Bahreini F; Soltanian AR; Mehdipour P
    Breast Cancer; 2015 Nov; 22(6):615-25. PubMed ID: 24718809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.
    Atkinson R; Mollerup J; Laenkholm AV; Verardo M; Hawes D; Commins D; Engvad B; Correa A; Ehlers CC; Nielsen KV
    Arch Pathol Lab Med; 2011 Aug; 135(8):1010-6. PubMed ID: 21809992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on Immunohistochemical Analysis in Breast Lesions.
    Peng Y; Butt YM; Chen B; Zhang X; Tang P
    Arch Pathol Lab Med; 2017 Aug; 141(8):1033-1051. PubMed ID: 28574279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
    Green IF; Zynger DL
    Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
    Nwafor CC; Keshinro SO
    Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?
    Pennacchia I; Vecchio FM; Carbone A; Arena V
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):31-5. PubMed ID: 25356940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rate.
    Sarode VR; Xiang QD; Christie A; Collins R; Rao R; Leitch AM; Euhus D; Haley B
    Arch Pathol Lab Med; 2015 Jul; 139(7):922-8. PubMed ID: 26125432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting OncoDX recurrence scores with immunohistochemical markers: effect of stromelysin.
    Bradshaw SH; Pidutti D; Gravel DH; Song X; Robertson SJ
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):26-30. PubMed ID: 25153499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization.
    Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
    Cancer; 2012 Feb; 118(4):914-23. PubMed ID: 21800290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival.
    Kakar S; Puangsuvan N; Stevens JM; Serenas R; Mangan G; Sahai S; Mihalov ML
    Mol Diagn; 2000 Sep; 5(3):199-207. PubMed ID: 11070154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.